Screener
CG Oncology CGON Q2 2026 earnings
Reported August 6, 2026 · Before market open
Revenue$1.2MBeat by $796.2K
EPS-$0.90Miss by $0.24
Revenue estimate$360.8K
EPS estimate-$0.66
“This quarter we have made significant progress across our clinical, regulatory, manufacturing and commercial-readiness initiatives, positioning the Company for long-term success. PIVOT-006 has accrued the vast majority of the target events, and we look forward to sharing topline results soon. We are confident in the potential of cretostimogene and are committed to delivering what we believe will be a backbone therapy for patients.”
Next report
Nov 13, 2026 (in 2 months)Revenue estimate$547.7K
EPS estimate-$0.86
Segments
By product
Versus estimates
Revenue
Q2 2026$1.2MBeat by $796.2K
Q1 2026$1.1MBeat by $630.0KQ4 2025$2.3MBeat by $1.8MQ3 2025$1.7MBeat by $1.6MQ1 2025$52.0KMiss by $66.2KDiluted EPS
FAQ
- When did CG Oncology report Q2 2026 earnings?
- CG Oncology (CGON) reported Q2 2026 earnings on August 6, 2026 before market open.
- What were CG Oncology's Q2 2026 revenue and EPS?
- CG Oncology reported revenue of $1.2M and eps of $-0.90 for Q2 2026.
- Did CG Oncology beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $360.8K by $796.2K. EPS missed the consensus estimate of $-0.66 by $0.24.
- How did CG Oncology's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps declined 66.7% from $-0.54.
- Where can I find CG Oncology's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-336886) and the 10-Q periodic report (0001193125-26-336918) directly on SEC EDGAR. The filing index links above go to sec.gov.
